The Valley Desk

Clinical trial reportInflammatory bowel diseasesPublished

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Inflammatory bowel diseases
Published
Subject terms
Humans; Crohn Disease; Treatment Outcome; Remission Induction; Severity of Illness Index; Follow-Up Studies; Adult; Middle Aged; Female; Male; Young Adult; Antibodies, Monoclonal, Humanized
PubMed ID
42065683
PubMed Central ID
PMC13533210
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal